Preclinical development of EXT608, an investigational parathyroid hormone derivative with extended half-life for the treatment of hypoparathyroidism

Preclinical development of EXT608, an investigational parathyroid hormone derivative with extended half-life for the treatment of hypoparathyroidism

GPCR Target: PTHR1

Authors: Daniel B. Hall, et al.

Journal: JBMR Plus, Volume 8, Issue 6, June 2024, ziae045.

Year Published: 2024

Leave a Reply